Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.
Risk and Volatility
Fate Therapeutics has a beta of 2.53, meaning that its stock price is 153% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.
Profitability
This table compares Fate Therapeutics and Neuphoria Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -2,056.79% | -58.89% | -39.39% |
| Neuphoria Therapeutics | N/A | -76.93% | -54.76% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $6.65 million | 38.74 | -$136.32 million | ($1.09) | -2.03 |
| Neuphoria Therapeutics | $15.65 million | 1.67 | -$370,000.00 | ($11.06) | -0.44 |
Neuphoria Therapeutics has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Neuphoria Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings for Fate Therapeutics and Neuphoria Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 3 | 3 | 0 | 2.29 |
| Neuphoria Therapeutics | 1 | 2 | 1 | 0 | 2.00 |
Fate Therapeutics currently has a consensus price target of $5.13, suggesting a potential upside of 131.90%. Neuphoria Therapeutics has a consensus price target of $21.00, suggesting a potential upside of 333.88%. Given Neuphoria Therapeutics’ higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Fate Therapeutics.
Summary
Fate Therapeutics beats Neuphoria Therapeutics on 9 of the 14 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
